{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:47Z","timestamp":1792798787859,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118548","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:55:41Z","timestamp":1792248941000},"page":"118548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["Metabolism-mediated herb-drug interaction between milk thistle and resmetirom in MCD diet-induced metabolic dysfunction-associated steatohepatitis rat model"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0449-4282","authenticated-orcid":false,"given":"Siva Nageswara Rao","family":"Gajula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Savana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi Yadav","family":"Saripilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Vineela","family":"Nalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.118548_b0005","first-page":"60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, touchREVIEWS","volume":"19","author":"Karim","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2026.118548_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118548_b0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/10600280241259528","article-title":"Resmetirom: the first Food and Drug Administration\u2013approved medication for nonalcoholic steatohepatitis (NASH)","volume":"59","author":"Guirguis","year":"2025","journal-title":"Ann. Pharmacother."},{"issue":"7","key":"10.1016\/j.bcp.2026.118548_b0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/00498254.2026.2687126","article-title":"Pharmacokinetics, mass balance and metabolic profiling of resmetirom in healthy subjects and nonclinical metabolism and disposition","volume":"56","author":"Hennan","year":"2026","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.bcp.2026.118548_b0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/00185787241278571","article-title":"Resmetirom","volume":"60","author":"Levien","year":"2025","journal-title":"Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.bcp.2026.118548_b0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3138\/canlivj-2023-0021","article-title":"Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"7","author":"Malik","year":"2024","journal-title":"Canadian Liver Journal"},{"issue":"2","key":"10.1016\/j.bcp.2026.118548_b0035","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/1534735407301825","article-title":"Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies","volume":"6","author":"Kroll","year":"2007","journal-title":"Integr. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.118548_b0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/life10070106","article-title":"Pharmacokinetic interactions between herbal medicines and drugs: their mechanisms and clinical relevance","volume":"10","author":"Rombol\u00e0","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.bcp.2026.118548_b0045","doi-asserted-by":"crossref","DOI":"10.1002\/bdd.70034","article-title":"Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb\u2013Drug Interaction Investigation","author":"Gajula","year":"2026","journal-title":"Biopharm. Drug Dispos."},{"issue":"11","key":"10.1016\/j.bcp.2026.118548_b0050","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1124\/dmd.107.016410","article-title":"Silybin is metabolized by cytochrome P450 2C8 in vitro","volume":"35","author":"Jan\u010dov\u00e1","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.bcp.2026.118548_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tiv.2010.09.001","article-title":"Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities","volume":"25","author":"Doehmer","year":"2011","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bcp.2026.118548_b0060","unstructured":"F. Food, Guidance for industry: bioanalytical method validation, http:\/\/www. fda. gov\/cder\/Guidance\/4252fnl. pdf (2001)."},{"key":"10.1016\/j.bcp.2026.118548_b0065","unstructured":"C.f.M.P.f.H. Use, Guideline on bioanalytical method validation, European medicines agency 44 (2011) 1\u201323."},{"issue":"2","key":"10.1016\/j.bcp.2026.118548_b0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/bdd.70006","article-title":"The influence of a rat model of depression and gastric ulcer on the pharmacokinetics of encorafenib","volume":"46","author":"Gajula","year":"2025","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.bcp.2026.118548_b0075","doi-asserted-by":"crossref","unstructured":"U.S. Pharmacopeia, Milk Thistle Capsules, 2022. https:\/\/doi.org\/10.31003\/USPNF_M54067_05_01.","DOI":"10.31003\/USPNF_M54067_05_01"},{"issue":"25","key":"10.1016\/j.bcp.2026.118548_b0080","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1007\/s00216-015-8925-6","article-title":"Optimization and single-laboratory validation of a method for the determination of flavonolignans in milk thistle seeds by high-performance liquid chromatography with ultraviolet detection: E. Mudge et al","volume":"407","author":"Mudge","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118548_b0085","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1046\/j.1440-1746.2003.03198.x","article-title":"Rodent nutritional model of non\u2010alcoholic steatohepatitis: species, strain and sex difference studies","volume":"18","author":"Kirsch","year":"2003","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118548_b0090","article-title":"A unique in vivo pharmacokinetic profile, in vitro metabolic stability and hepatic first-pass metabolism of garcinol, a promising novel anticancer phytoconstituent, by liquid chromatography\u2013mass spectrometry","volume":"2","author":"Rao Gajula","year":"2023","journal-title":"RPS Pharm. Pharmacolo. Rep."},{"key":"10.1016\/j.bcp.2026.118548_b0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbi.2017.04.025","article-title":"The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes","volume":"271","author":"Albassam","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.bcp.2026.118548_b0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/dmd.112.048272","article-title":"Interaction of silymarin flavonolignans with organic anion-transporting polypeptides","volume":"41","author":"K\u00f6ck","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bcp.2026.118548_b0105","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1002\/ptr.7049","article-title":"Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin\u2010drug interactions","volume":"35","author":"Lynch","year":"2021","journal-title":"Phytother. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118548_b0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3892\/ijmm.2012.1029","article-title":"Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells","volume":"30","author":"Kim","year":"2012","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118548_b0115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1124\/jpet.109.161612","article-title":"A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis","volume":"332","author":"Serviddio","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118548_b0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10620-007-9900-7","article-title":"Methionine deficiency and hepatic injury in a dietary steatohepatitis model","volume":"53","author":"Oz","year":"2008","journal-title":"Dig. Dis. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2026.118548_b0125","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor\u2010\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non\u2010alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"10213","key":"10.1016\/j.bcp.2026.118548_b0130","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2026.118548_b0135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.etp.2010.04.009","article-title":"Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis","volume":"63","author":"Aghazadeh","year":"2011","journal-title":"Exp. Toxicol. Pathol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:02:17Z","timestamp":1792796537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":27,"alternative-id":["S0006295226008907"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118548","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism-mediated herb-drug interaction between milk thistle and resmetirom in MCD diet-induced metabolic dysfunction-associated steatohepatitis rat model","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118548"}}